Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZYMERGEN INC.

(ZY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ZYMERGEN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Zymergen Inc. - ZY

10/01/2021 | 10:51pm EST

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until October 4, 2021 to file lead plaintiff applications in a securities class action lawsuit against Zymergen Inc. (NasdaqGS: ZY), if they purchased the Company’s shares issued in connection with its April 2021 initial public stock offering (the “IPO”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased shares of Zymergen and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-zy/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by October 4, 2021.

About the Lawsuit

Zymergen and certain of its executives are charged with failing to disclose material information in its IPO Registration Statement and Prospectus, violating federal securities laws. On August 3, 2021, post-market, the Company disclosed that it “recently became aware of issues with its commercial product pipeline that will impact the Company’s delivery timeline and revenue projections,” specifically, that “several key target customers encountered technical issues in implementing Hyaline [its first product] into their manufacturing processes.” The Company also disclosed that its total addressable market appeared to be smaller than previously expected and it “no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.”

On this news, shares of Zymergen fell $26.58 per share, or 76%, to close at $8.25 per share on August 4, 2021, representing a nearly 73% decline from the IPO price.

The case is Shankar v. Zymergen Inc., et al., 21-cv-06028.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.


ę Business Wire 2021
All news about ZYMERGEN INC.
11/22INSIDER BUY : Zymergen
MT
11/15ZYMERGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/11The Law Offices of Frank R. Cruz Announces Investigation of Zymergen Inc. (ZY) on Behal..
BU
11/10Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigati..
BU
11/03ZYMERGEN : Q3 Earnings Snapshot
AQ
11/03Zymergen Reports Preliminary Third Quarter 2021 Financial Results and Provides Business..
PU
11/03Earnings Flash (ZY) ZYMERGEN Reports Q3 Revenue $4.1M, vs. Street Est of $3.41M
MT
11/03Zymergen Reports Preliminary Third Quarter 2021 Financial Results and Provides Business..
AQ
10/26Zymergen to Report Third Quarter 2021 Financial Results on November 3, 2021
GL
10/21ZYMERGEN INC. : Entry into a Material Definitive Agreement, Costs Associated with Exit or ..
AQ
More news
Analyst Recommendations on ZYMERGEN INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -372 M - -
Net cash 2021 313 M - -
P/E ratio 2021 -2,07x
Yield 2021 -
Capitalization 972 M 972 M -
EV / Sales 2021 38,9x
EV / Sales 2022 53,8x
Nbr of Employees 758
Free-Float 90,7%
Chart ZYMERGEN INC.
Duration : Period :
Zymergen Inc. Technical Analysis Chart | ZY | US98985X1000 | MarketScreener
Technical analysis trends ZYMERGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 7
Last Close Price 9,49 $
Average target price 9,50 $
Spread / Average Target 0,11%
EPS Revisions
Managers and Directors
Jay T. Flatley Chairman & Chief Executive Officer
Enakshi Singh Chief Financial Officer
Zachariah Serber Director & Chief Science Officer
Jed Dean Vice President-Operations & Engineering
Aaron Kimball Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ZYMERGEN INC.0.00%972
SHIN-ETSU CHEMICAL CO., LTD.5.49%69 534
BASF SE-10.41%60 017
DUPONT DE NEMOURS, INC.8.34%39 915
ROYAL DSM N.V.36.22%36 863
PIDILITE INDUSTRIES LIMITED25.45%14 988